Dachaigh › Aillse Sgamhain Neo-chealla-beag › California › San Francisco
Sgrùdaidhean clionaigeach Aillse Sgamhain Neo-chealla-beag ann an San Francisco, CA
Tha 36 sgrùdaidhean airson Aillse Sgamhain Neo-chealla-beag a’ lorg phàirtichean aig làraichean ann agus timcheall air San Francisco (taobh a-staigh mu 30 mìle). Fosglaidh sgrùdadh gus faicinn cò as urrainn pàirt a ghabhail agus mar a chuireas tu fios air an sgioba.
Teacsa sgrùdaidh oifigeil (Beurla)
A’ fastadh airson sgrùdadh an seo? Seall e aig mullach na duilleige seo — $99 airson 30 latha →
A Study of ZW251 in Participants With Advanced Solid Tumors
A’ fastadhÌre 1
- UCSF Comprehensive Cancer Center, San Francisco
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
A’ fastadhÌre 3
- California Pacific Medical Center-Pacific Campus, San Francisco
- Kaiser Permanente-San Francisco, San Francisco
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
A’ fastadhÌre 3
- UCSF Medical Center at Mission Bay ( Site 0178), San Francisco
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
A’ fastadhÌre 3
- Kaiser Permanente-San Francisco, San Francisco
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
A’ fastadhÌre 3
- San Francisco Oncology Associates ( Site 0066), San Francisco
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
A’ fastadhÌre 2
- UCSF Zuckerberg San Francisco General Hospital, San Francisco
Intratumoral N17350 in Advanced Solid Tumors
A’ fastadhÌre 1/2
- University of California, San Francisco, San Francisco
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
A’ fastadhÌre 3
- Research Site, San Francisco
A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation
A’ fastadhÌre 3
- UCSF Health - UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
A’ fastadhÌre 3
- University of California San Francisco, San Francisco
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
A’ fastadhÌre 1/2
- University of California, San Francisco (UCSF), San Francisco
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
A’ fastadhÌre 2/3
- San Francisco Veterans Affairs Medical Center, San Francisco
- UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
A’ fastadhÌre 1/2
- UCSF Helen Diller Medical Center at Parnassus Heights - Neurology, San Francisco
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
A’ fastadhÌre 3
- California Pacific Medical Center, San Francisco
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
A’ fastadhÌre 1
- University of California San Francisco, San Francisco
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
A’ fastadhÌre 1
- University of California San Francisco, San Francisco
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
A’ fastadhÌre 1/2
- University of California San Francisco, San Francisco
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
A’ fastadhÌre 3
- UCSF Medical Center-Mission Bay, San Francisco
Hippocampal Avoidance in Craniospinal Irradiation for the Treatment of Leptomeningeal Metastases From Breast Cancer or Non-small Cell Lung Cancer
A’ fastadhÌre 2
- University of California San Francisco, San Francisco
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
A’ fastadhÌre 1/2
- UCSF Medical Center - Mission Bay, San Francisco
Biomarkers for Risk Stratification in Lung Cancer
A’ fastadhSgrùdadh amharc
- Zuckerberg San Francisco General Hospital and Trauma Center, San Francisco
- San Francisco VA Medical Center, San Francisco
- University of California, San Francisco, San Francisco
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
A’ fastadhÌre 2
- California Pacific Medical Center-Pacific Campus, San Francisco
- Kaiser Permanente-San Francisco, San Francisco
- Veterans Affairs Medical Center - San Francisco, San Francisco
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
A’ fastadhÌre 1
- University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
A’ fastadhÌre 2
- California Pacific Medical Center-Pacific Campus, San Francisco
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
A’ fastadhÌre 2/3
- Kaiser Permanente-San Francisco, San Francisco
- Veterans Affairs Medical Center - San Francisco, San Francisco
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
A’ fastadhÌre 2
- California Pacific Medical Center-Pacific Campus, San Francisco
- Kaiser Permanente-San Francisco, San Francisco
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
A’ fastadh
- Zuckerberg San Francisco General, San Francisco
- Kaiser Foundation Research Institute, San Francisco
- University of San Francisco, San Francisco
Study of PF-07248144 in Advanced or Metastatic Solid Tumors
A’ fastadhÌre 2
- UCSF Medical Center at Mission Bay, San Francisco
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
A’ fastadhÌre 1/2
- University of California at San Francisco, San Francisco
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
A’ fastadhÌre 1/2
- University of California San Francisco (UCSF) - Helen Diller Family Comprehensive Cancer Center, San Francisco
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
A’ fastadhSgrùdadh amharc
- Kaiser Permanente-San Francisco, San Francisco
Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors
A’ fastadhÌre 1/2
- UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
A’ fastadhSgrùdadh amharc
- Massive Bio SYNERGY-AI site, San Francisco
A Study of NX-1607 in Adults With Advanced Malignancies
A’ fastadhÌre 1
- University of California, San Francisco, San Francisco
A Multicenter Cancer Biospecimen Collection Study
A’ fastadhSgrùdadh amharc
- Curebase, San Francisco
A Study of IBI363 in Subjects with Advanced Solid Malignancies
A’ fastadhÌre 2
- University of California, San Francisco (UCSF), San Francisco
Sgrùdaidhean Aillse Sgamhain Neo-chealla-beag ann am bailtean eile
- Houston, TX145 sgrùdaidhean
- New York City, NY121 sgrùdaidhean
- Arlington, VA104 sgrùdaidhean
- Nashville, TN97 sgrùdaidhean
- Boston, MA90 sgrùdaidhean
- Los Angeles, CA87 sgrùdaidhean
- St. Louis, MO73 sgrùdaidhean
- Chicago, IL61 sgrùdaidhean
- Baltimore, MD60 sgrùdaidhean
- San Antonio, TX59 sgrùdaidhean
- Columbus, OH57 sgrùdaidhean
- Washington, DC55 sgrùdaidhean
Sgrùdaidhean eile ann an San Francisco
- Aillse Prostata45 sgrùdaidhean
- Aillse a' bhroilleach43 sgrùdaidhean
- Aillse (gach seòrsa)35 sgrùdaidhean
- Fàilligeadh a' Chridhe29 sgrùdaidhean
- Ailse metastatach28 sgrùdaidhean
- Ailseachadh nan Sgamhan22 sgrùdaidhean
- Melanoma22 sgrùdaidhean
- Cancer Pancreatic20 sgrùdaidhean
- Cancer Ovarian19 sgrùdaidhean
- Aillse colorectal18 sgrùdaidhean
- Galarachd Cardiovasculach18 sgrùdaidhean
- Glioblastoma17 sgrùdaidhean
Bho ClinicalTrials.gov, dàta air a thogail 6 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.